ARAF and cancer: On the other hand, ARAF is a known proto-oncogene and member of the MAPK cascade which is frequently mutated in lung adenocarcinoma and its inhibition is a promising therapeutic target and thus its targeting by tRF-3021a could possibly be associated with cancer progression [61].